Whilst long established in breast cancer, the highly effective option of aromatase inhibitors as adjuvant maintenance treatment has never been thoroughly examined for its use in ovarian cancer due to the disinterest of pharmacological industries. Here, CYP19A1 is linked to breast cancer.